menu_open Columnists
We use cookies to provide some features and experiences in QOSHE

More information  .  Close

The Pharmaceutical Industry And Biotech Frontier Economy In Southeast Asia – OpEd

19 0
27.10.2026

The U.S. has imposed a 100% tariff on imported branded pharmaceuticals (delayed, with exemptions for domestic manufacturing), buffering ASEAN intermediates exporters while negotiations continue under Section 232.

ASEAN’s ~US$27 billion pharma market is growing at 8.1% CAGR, driven by demographics and demand for branded generics as affordable, trust-building entry points.

Singapore leads as a biotech hub, while Thailand, Vietnam and Indonesia expand capacity under government incentives and the 2022 ASEAN Pharmaceutical Regulatory Policy.

Using tariffs as tools of trade policy, the United States (U.S.) government has imposed a 100% tariff on imported branded or patented pharmaceutical products, though implementation has been postponed and delayed providing manufacturers time to negotiate exemptions. Drug manufacturers are exempt from the 100% tariff if they already have, or have started building, manufacturing facilities inside the United States. 

The tariffs on pharmaceutical products will impact many countries. For example, ASEAN member countries like Singapore where pharmaceuticals make up 13% of US-bound exports, primarily manufacture active ingredients or specialize in intermediate production rather than final branded formulations. This structure has buffered manufacturing plants against immediate punitive blows, though local media reported temporary postponements and ongoing bilateral trade negotiations to iron out exemptions.

The immense diversity across countries in the Southeast Asian region enabled these markets function as excellent case studies for developing broader emerging market strategies. Branded options help build consumer trust and counter illicit or unverified products in regions with developing supply chains. They offer budget-friendly alternatives to expensive, newly patented drugs where government health budgets and private reimbursements vary widely. Companies can use them to establish early market footprints before scaling up to complex therapeutics or biosimilars.

The Association of Southeast Asian Nations’ (ASEAN) pharmaceutical market is valued at approximately US$27 billion with a compound annual growth rate (CAGR) of 8.1%, nearly double the global average of 4.3% (Malaysian Reserve, 25 October 2026). While most Southeast Asian countries remain heavily reliant on pharmaceutical imports, the region is becoming increasingly attractive as a contract manufacturing destination. In Indonesia, foreign direct investment (FDI) in the chemical and pharma industry exceeded US $ 3.8 billion in 2025 but a decrease from US $ 4.1 billion in 2024. 

Table 1: Market Drivers vs. Established Barriers

Table 1 above shows market drivers and established barriers. This development is accelerated........

© Eurasia Review